Metabolic dysfunction-associated steatohepatitis (MASH) is often viewed through the lens of hepatic lipid accumulation, inflammation and fibrosis. A new study published in eGastroenterology shifts attention upstream, identifying intestinal neutral ceramidase as a gut-derived driver of MASH progression through its effects on microbial metabolism, epithelial signalling and intestinal barrier function.